Gilead Sciences (GILD) Change in Account Payables (2009 - 2026)

Gilead Sciences (GILD) has reported Change in Account Payables for 18 consecutive years, with $18.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables rose 111.11% year-over-year to $18.0 million; the trailing twelve-month figure through Jun 2026 stood at $86.0 million (up 152.94% YoY), and the FY2025 full-year result was -$132.0 million, down 145.52% from the prior year.
• Change in Account Payables advanced to $18.0 million in Q2 2026 per GILD's latest filing, from -$67.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $359.0 million in Q3 2024 and bottomed at -$272.0 million in Q1 2023.
• Historically, Change in Account Payables has averaged -$666666.7 across 5 years, with a median of -$36.0 million in 2023.
• The widest YoY moves for Change in Account Payables: up 1337.93% in 2024, down 2666.67% in 2024.
• Over 5 years, Change in Account Payables stood at $264.0 million in 2022, then tumbled by 116.29% to -$43.0 million in 2023, then sank by 34.88% to -$58.0 million in 2024, then slumped by 63.79% to -$95.0 million in 2025, then jumped by 118.95% to $18.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $18.0 million, -$67.0 million, and -$95.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.